Showing 20 of 136 recruiting trials for “fibrolamellar-hepatocellular-carcinoma”
Durvalumab and Tremelimumab in Resectable HCC
FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
RecruitingNCT05263830 ↗
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
👨⚕️ Manon ALLAIRE, Dr, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06060769 ↗
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
👨⚕️ Yaqin Zhang, MD, Ph.D, Fifth Affiliated Hospital, Sun Yat-Sen University📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06036563 ↗
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
👨⚕️ Anthony B El-Khoueiry, MD, University of Southern California📍 2 sites📅 Started Mar 2023View details ↗
The Application of Serum DNA Methylation for Patients With HCC
👨⚕️ Po-Yueh Chen, M.D, Ditmanson Medical Foundation Chiayi Christian Hospital📍 1 site📅 Started Mar 2023View details ↗
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
RecruitingNCT06806579 ↗
Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
👨⚕️ Francesco Tovoli, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 24 sites📅 Started Dec 2022View details ↗
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
👨⚕️ Cai Jian qiang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 5 sites📅 Started Nov 2022View details ↗
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
👨⚕️ Jessica Gartrell, MD, St. Jude Children's Research Hospital📍 2 sites📅 Started Nov 2022View details ↗
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
🏥 Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started Nov 2022View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →